BusinessGalectin Therapeutics Announces Results from Phase 2b NASH-CX TrialBy Nasdaq OMXDec 5, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017By Nasdaq OMXDec 4, 2017, 9:00 PM UTC